Foley Hoag LLP recently represented Waltham, MA-based Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs for a wide range of diseases, in its $51.5 million Series A financing.
Morphic Therapeutic was founded to translate the advances from the laboratory of Tim Springer, Ph.D. (Harvard Medical School, Boston Children’s Hospital) into new therapies for immunological, fibrotic, neoplastic and vascular diseases. Morphic Therapeutic is leveraging recent discoveries from Dr. Springer’s lab that may overcome the challenges that limited prior attempts to create small molecule integrin inhibitors.
The round was co-led by biotech investors SR One and Pfizer Venture Investments, who were also joined by new investors Omega Funds and AbbVie, and existing founding investors Polaris Partners, T. A. Springer, Schrödinger, Inc. and ShangPharma Investment Group.
Foley Hoag partner Mark Haddad and associate Patrick Connolly represented Morphic in the transaction, with assistance from partner Earl Mellott and associate Jeremy Arak.